These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22241961)

  • 1. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
    Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
    Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
    PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
    Mao TL; Fan KF; Liu CL
    Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.
    Luker KE; Mihalko LA; Schmidt BT; Lewin SA; Ray P; Shcherbo D; Chudakov DM; Luker GD
    Nat Med; 2011 Dec; 18(1):172-7. PubMed ID: 22138753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
    Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
    Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
    Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
    Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
    Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
    Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
    Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging CXCR4 signaling with firefly luciferase complementation.
    Luker KE; Gupta M; Luker GD
    Anal Chem; 2008 Jul; 80(14):5565-73. PubMed ID: 18533683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
    Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
    J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging ligand-dependent activation of CXCR7.
    Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
    Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.
    Ray P; Lewin SA; Mihalko LA; Lesher-Perez SC; Takayama S; Luker KE; Luker GD
    Biochem J; 2012 Mar; 442(2):433-42. PubMed ID: 22142194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
    Benedicto A; Romayor I; Arteta B
    Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
    Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
    J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
    Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.
    Luker K; Gupta M; Luker G
    Biotechniques; 2009 Jul; 47(1):625-32. PubMed ID: 19594447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
    Obermajer N; Muthuswamy R; Odunsi K; Edwards RP; Kalinski P
    Cancer Res; 2011 Dec; 71(24):7463-70. PubMed ID: 22025564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.